Drug intelligence / Profile preview

diamorphine + morphine

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intramuscular, Subcutaneous, Intravenous

Overview

Diamorphine + morphine is a combination of two potent opioid analgesics. Diamorphine (heroin) is a narcotic analgesic that acts as a pro-drug of morphine, while morphine is a strong opioid that directly activates opioid receptors. Both drugs act as agonists at opioid receptors (μ, κ, and δ subtypes) to produce analgesia, sedation, and euphoria. This combination would provide powerful pain relief for severe pain, though it's not commonly prescribed as a specific combination since diamorphine is metabolized to morphine in the body.

Other names: heroin + morphinediacetylmorphine + morphine

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on diamorphine + morphine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on diamorphine + morphine.

Explore the full profile